Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis

• Published in: Supportive care in cancer Vol. 29; no. 12; pp. 7461 - 7469
• Main Authors: Gu, Jialin, Lu, Hong, Chen, Chen, Gu, Zhancheng, Hu, Miao, Liu, Ling, Yu, Jialin, Wei, Guoli, Huo, Jiege
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer; Springer Nature B.V
• Subjects: Antineoplastic Agents - adverse effects; Cancer; Carboplatin; Chemotherapy; Diabetes; Diabetes Mellitus - chemically induced; Diabetes Mellitus - epidemiology; Diabetics; Humans; Medicine; Medicine & Public Health; Meta-analysis; Nursing; Nursing Research; Odds Ratio; Oncology; Oncology, Experimental; Original; Original Article; Pain Medicine; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - epidemiology; Peripheral neuropathy; Rehabilitation Medicine; Risk Factors; Vincristine; China; Risk; Diabetes mellitus (DM); Chemotherapy-induced peripheral neuropathy (CIPN); Meta-analysis
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06321-7

Background To identify the association between diabetes mellitus (DM) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) through a systematic review and meta-analysis. Methods An electronic literature search was conducted in PubMed, Embase, Web of Science, the Wanfang database, the VIP Journals database (CQVIP), the China National Knowledge Infrastructure (CNKI) database, and the China Biology Medicine database (Sinomed) between January 2010 and January 2021. Articles were included if they investigated CIPN and DM. Stata 15.1 was used to analyze the data. Results We examined 8923 cancer patients from 25 studies comprising 9 cohort studies and 16 case–control studies. Meta-analysis showed that there was a statistically significant positive correlation between DM and CIPN (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.38–1.85, P  < 0.001). Egger’s test ( P  = 0.824) showed no evidence of publication bias. The positive associations did not significant differ by study type, study quality, evaluation instrument, and type of antineoplastic drug. Omission of any single study had little effect on the combined risk estimate. Little evidence of heterogeneity was observed. Conclusion This meta-analysis provides evidence of a significant positive association between DM and risk of CIPN. Furthermore, a more detailed evaluation is warranted for cancer patients with diabetes when they are treated with antineoplastic drugs that have the potential to cause peripheral neuropathy.